Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
The Microbiome Links Seres And Nestlé …
by Michael McCoy
January 18, 2016
| A version of this story appeared in
Volume 94, Issue 3
Seres Therapeutics is joining with Nestlé Health Science to develop drugs that harness the gut microbiome to treat Clostridium difficile infection and inflammatory bowel disease. Seres will receive $120 million up front and could get up to $1.9 billion in total payments. In exchange it will give Nestlé rights outside the U.S. and North America to its lead candidate, SER-109, as well as other products. SER-109, which has completed a Phase Ib/II study, treats C. difficile infection with spores of beneficial bacteria derived from stool samples. Nestlé also invested in Seres twice last year.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter